or Try an Advanced Search...

    Digestive Diseases Stocks List

    Symbol Grade Name % Change
    IRWD F Ironwood Pharmaceuticals, Inc. -17.12
    LUCD D Lucid Diagnostics Inc. -2.35
    BIVI F BioVie Inc. 0.62
    MIRM F Mirum Pharmaceuticals, Inc. 3.04
    MCRB D Seres Therapeutics, Inc. 37.44
    View As Page of Charts
    Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic Medical Devices
    Related Stock Lists: Gastroenterology Hepatology Liver Medicine Acid Antibiotics Antimicrobial Resistance Autoimmune Disease Bile Acid Cancer Cardiovascular Disease Cdi Central Nervous System Disorders Cholestasis Chronic Idiopathic Constipation Clinical Development Clinical Medicine Clostridioides Difficile Clostridium Difficile Clostridium Difficile Infection

    Related ETFs - A few ETFs which own one or more of the above listed Digestive Diseases stocks.

    Symbol Grade Name Weight
    ACTV C LeaderShares Activist Leaders ETF 3.63
    BBP C BioShares Biotechnology Products Fund 2.89
    XBI D SPDR S&P Biotech ETF 1.82
    SBIO C ALPS Medical Breakthroughs ETF 1.61
    LABU D Direxion Daily S&P Biotech Bull 3X Shares 1.09
    View all Digestive Diseases ETFs...
    Compare ETFs
    Compare ACTV to BBP Compare ACTV to XBI Compare BBP to XBI

        Digestive Diseases Stocks Recent News

        Date Stock Title
        May 9 MIRM Q1 2024 Mirum Pharmaceuticals Inc Earnings Call
        May 9 IRWD Ironwood Pharmaceuticals Non-GAAP EPS of -$0.02 misses by $0.17, revenue of $74.88M misses by $30.82M
        May 9 MCRB Seres Therapeutics First Quarter 2024 Earnings: US$0.28 loss per share (vs US$0.56 loss in 1Q 2023)
        May 9 IRWD Ironwood Pharmaceuticals Reports First Quarter 2024 Results
        May 9 MIRM Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings Call Transcript Highlights: Soaring Sales and ...
        May 9 MCRB Seres Therapeutics Inc (MCRB) Q1 2024 Earnings Call Transcript Highlights: Strategic Insights ...
        May 8 MIRM Mirum Pharmaceuticals GAAP EPS of -$0.54 misses by $0.14, revenue of $69.2M misses by $0.97M
        May 8 MIRM Mirum Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update
        May 8 IRWD Ironwood Pharmaceuticals Q1 2024 Earnings Preview
        May 8 MCRB Seres Therapeutics Reports Q1 2024 Earnings: Surpasses Revenue Estimates
        May 8 MCRB Seres Therapeutics GAAP EPS of -$0.27 beats by $0.07
        May 8 MCRB Seres Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
        May 7 MIRM Mirum Pharmaceuticals Q1 2024 Earnings Preview
        May 7 MIRM Mirum Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
        May 7 MCRB Seres Therapeutics Q1 2024 Earnings Preview
        May 7 MIRM Mirum Announces Publication of Phase 3 MARCH Data in The Lancet Demonstrating Benefits of LIVMARLI (maralixibat) in patients with PFIC
        May 6 IRWD Ironwood Pharmaceuticals to Participate in The Citizens JMP Life Sciences Conference
        May 6 MCRB Seres Therapeutics to Announce First Quarter 2024 Financial Results and Business Update on May 8, 2024
        Related Industries: Biotechnology Drug Manufacturers - Specialty & Generic Medical Devices
        Related Stock Lists: Gastroenterology Hepatology Liver Medicine Acid Antibiotics Antimicrobial Resistance Autoimmune Disease Bile Acid Cancer Cardiovascular Disease Cdi Central Nervous System Disorders Cholestasis Chronic Idiopathic Constipation Clinical Development Clinical Medicine Clostridioides Difficile Clostridium Difficile Clostridium Difficile Infection
        Digestive Diseases

        Karger Publishers (also: Karger Medical and Scientific Publishers, S. Karger AG) is an academic publisher of scientific and medical journals and books. The current CEO is Gabriella Karger.

        More about Digestive Diseases
        Browse All Tags